Company intelligence / Profile preview

Indaptus Therapeutics

New York City, New York, United Statesindaptusrx.com ↗

Ownership: Public · INDP
Employees: ~42
Development stage: Phase 2

Overview

Indaptus’ lead candidate Decoy20 has shown broad immune activation in multiple tumor types in Phase I trials with a favorable safety profile to date. The company has initiated higher-dose cohorts and plans combination studies with checkpoint inhibitors in early/mid–2025. No new clinically significant treatment-related adverse effects have been observed so far. Preclinical data support durable anti-tumor responses both as monotherapy and in combination settings.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Attenuated and killed non-pathogenic gram-negative bacteriaImmunotherapy agents (multi-PAMP bacterial therapies)
Industry: Biotech

Drug pipeline

4 assets

Decoy20

3 more assets in the full pipeline.

Request access →

Partnerships

Merck Sharp & Dohme*LTS Lohmann Therapie-Systeme AG*

Financials

Market cap: $235.5M
Total revenue: $0
Enterprise value: $224M

Beyond the preview

Go deeper on Indaptus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Indaptus Therapeutics.

Explore the full profile